ADA 2019—Duodenal mucosal resurfacing promising in interim analysis


  • Emily Willingham, PhD
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A small trial of duodenal mucosal resurfacing (Revita DMR; Fractyl) plus drug (liraglutide) and lifestyle treatment for type 2 diabetes (T2D) has yielded promising interim results.
  • Of 13 patients who reached 6-month follow-up, 85% are insulin-independent.
  • Liver fat content also had decreased by 45%, and BP and weight improved.

Why this matters

  • DMR is a same-day endoscopic procedure that leaves the duodenal mucosa ablated, altering metabolic signaling, says Fractyl. 
  • The company has conducted clinical studies involving 200 patients, with results suggesting improvements up to 1 year in blood glucose, liver fat, cardiovascular risk, weight loss, without lifestyle intervention.

Key results

  • 11/13 patients (85%) who reached 6-month follow-up are insulin-independent.
  • The other 3 of the original 16 enrollees have not yet reached 6 months.
  • Liver fat decreased on average by 45% (baseline was 8.5% liver fat).
  • The company says that the safety profile is acceptable and DMR was well-tolerated.

Study design

  • Single-center study, 16 participants with T2D.
  • Participants underwent DMR, discontinued insulin.
  • At day 14, they began liraglutide (titration to 1.8 mg/day).
  • Lifestyle counseling provided throughout.
  • Endpoint: percentage insulin-free, HbA1c ≤59 mmol/mol at 6 months.
  • Funding: Fractyl, others.

Limitations

  • Conference presentation, very small study population, no control group.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit